ROMO1

Across TCGA pan-cancer cohorts, ROMO1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ROMO1 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ROMO1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ROMO1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and COAD show a favorable association.

CCRCC, LSCC, and COAD are the cancer types where ROMO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.399	0.734	.005	34	view →
LSCC	DFS	Tertile	II,III,IV	0.922	0.578	.004	20	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.909	.041	18	view →
GBM	DFS	Median	All	0.218	0.416	.034	2	view →
HNSC	DFS	Tertile	IV	0.731	0.541	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ROMO1–CCRCC (DFS)

Open the CCRCC breakdown →